SEC filing record
Primary Source · SEC.gov

OrbiMed Private Investments X, LP

Fund Vehicle2025 vintageRegulation D Rule 506(b) with Investment Company Act 3(c)(7); $0 in Form D's minimum-investment field
Latest signalOffering upsizedForm D/A · 2026-10-169 events: 2 large raise, 2 sold increased, 2 investors increasedLast filing 2026-10-16

Raised

$1.9B

Investors

131

Min Invest

None stated

AltStreet Verified Issuer badge

Is this your company or fund? Claim this page free, or verify it and carry the Verified Issuer mark.

AltStreet Analysis

·

Generated from EDGAR primary sources

Filed a Form D on September 29, 2025 with a $1,750,000,000 offering amount; the Form D/A of April 30, 2026 reported $1,669,183,000 sold to 119 investors, and the Form D/A of October 16, 2026 reports $1,921,099,472 sold to 131 investors with the offering amount raised to match and $0 remaining, the day after OrbiMed announced over $1.9 billion raised for the fund. First sale September 30, 2025. Sales compensation to UBS Switzerland AG and Merrill Lynch, Pierce, Fenner & Smith (commissions reported as $0, estimate). Signed by W. Carter Neild.

Life sciences venture capital fund (U.S. and Europe): a Delaware limited partnership organized in 2025 at 601 Lexington Avenue, New York; general partner OrbiMed Capital GP X, LP, whose general partner OrbiMed Capital GP X LLC is managed by OrbiMed Advisors LLC. Raised alongside OrbiMed Asia Partners VI, L.P. (CIK 0002087034, $1,045,599,648 sold). Predecessor OrbiMed Private Investments IX's last located notice (April 2023) reported $1,849,550,000 sold to 141 investors.

EDGAR Filing Data

Form D — Primary Source

View on SEC.gov
CIK Number0002087033
Entity NameOrbiMed Private Investments X, LP
ExemptionRule 506(b), Section 3(c), Section 3(c)(7)
What the exemption meansRule 506(b) of Regulation D: securities may be sold to an unlimited number of accredited investors and up to 35 non-accredited investors who meet the rule's sophistication standard, without general solicitation or advertising. Section 3(c) of the Investment Company Act of 1940: the issuer is a pooled investment vehicle relying on an exclusion from registration as an investment company. Section 3(c)(7) of the Investment Company Act: the fund is excluded from investment-company registration because every investor is a qualified purchaser, generally an individual with at least $5 million in investments or an institution with at least $25 million.
Entity TypeLimited Partnership
Jurisdiction of OrganizationDelaware
Year Organized2025
Issuer Address601 Lexington Avenue, 54th Floor, New York, NY 10022
Phone(212) 739-6400
Industry / Fund TypePooled Investment Fund · Private Equity Fund
Investment Company ActExcluded under Section 3(c)(7) (qualified purchasers only)
Securities TypePooled Investment Fund
First Sale DateSeptember 30, 2025
Filing DateOctober 16, 2026
Accession Number0002087033-26-000002
Total Offering Amount$1,921,099,472
Total Amount Sold$1,921,099,472
Amount Remaining$0
Amount Sold NoteCombined figure across related vehicles: The total amount sold includes capital committed by the General Partner.
Total Investors131
Non-Accredited InvestorsNone
Minimum Investment$0 (no stated minimum)
Offering DurationOne year or less
Sales Commissions$0 (to UBS Switzerland AG and 1 other)
Finders' Fees$0
Proceeds to Related Persons$0
Revenue RangeNot Applicable
State (Issuer Address)NY
Amendment Count2 amendments filed (3 Form D filings)
Signed ByW. Carter Neild, Member of OrbiMed Advisors

Filings on Record

Every filing AltStreet's ledger holds for this CIK, newest first. Each opens the SEC archive folder.

AltStreet Coverage

Original reporting from AltStreet's daily EDGAR monitoring covering this entity's filings.

All AltStreet news

In the Terminal

Filing events

9

latest Oct 16, 2026

Critical / warning

1 / 1

4 watch · 3 info

Statements extracted

0

none on file

NAV prints

0

none on file

Offering chains

1

closed

Latest event Large raise · Oct 16, 2026

SEC.gov
Open in the terminal Watch this issuerInvestor $149/mo unlocks the values; Pro $349/mo adds the universe.

Fund family Part of the OrbiMed Private Investments family: 4 vehicles across 4 generations · adviser of record Orbimed Advisors LLC · full family and the filing behind each link in the terminal

Investor

  • The full fund family and any related vehicles (parallel, feeder, successor, sibling series) with the filing that shows each link
  • The dated record: 45 facts with source, effective date and capture date, viewable as AltStreet knew them on any past day
  • 9 filing events with values and deltas, latest 2026-10-16, and alerts on the next one
  • 1 offering timeline: velocity, share raised, first-sale lag, stalled flags

Pro

  • This issuer against its cohort: rank by velocity and share raised among offerings filed the same quarter
  • The same events, statements and NAV moves across every issuer, screenable, with unlimited watches and CSV

Counts and dates above are the free record. The values, the series and the comparisons are the seat. Loading your view…

Adviser of Record (Form ADV)

Orbimed Advisors LLC

CRD 118608 · SEC-registered adviser · lists this fund on Schedule D 7.B.(1) as a other private fund

Auditor named on Form ADV: Kpmg LLP · PCAOB-registered per the adviser

From the adviser's Form ADV as loaded from the SEC bulk data, joined on this issuer's Form D file number. Fund-level figures and the adviser's full fund roster are in the terminal.

Related Persons (Form D)

Executive officers, directors, and promoters listed on the SEC Form D filing. Source: SEC.gov.

Item 3 changed on the Form D filed 2026-10-16: 0 related persons added and 1 removed against the filing of 2026-04-30; 11 now listed. The names are in the Terminal feed.

OrbiMed Capital GP X, LP

Executive Officer · New York, NY

General Partner of the Issuer

OrbiMed Capital GP X LLC

Executive Officer · New York, NY

General Partner of the GPLP

OrbiMed Advisors LLC

Executive Officer · New York, NY

Managing Member of the GPLLC

Carl Gordon

Executive Officer · New York, NY

Member of OrbiMed Advisors

W. Carter Neild

Executive Officer · New York, NY

Member of OrbiMed Advisors

Placement Agents and Sales Compensation (Form D)

Who the issuer reported paying to sell the securities (Form D Item 12), with the FINRA registration number the filer gave. Source: SEC.gov.

UBS Switzerland AG

Associated broker-dealer: None · Zurich, V8 and outside the United States

MERRILL LYNCH, PIERCE, FENNER & SMITH INCORPORATEDCRD 7691 on BrokerCheck

Associated broker-dealer: None · NEW YORK, NY · Soliciting in all states

Questions About OrbiMed Private Investments X, LP

Each answer is built from the values on the SEC filing and the AltStreet ledger, not from the issuer's marketing.

What is OrbiMed Private Investments X, LP?

OrbiMed Private Investments X, LP is a Delaware limited partnership organized in 2025 that filed a Form D with the SEC on October 16, 2026 as a private equity fund. The filing claims Rule 506(b), Section 3(c), Section 3(c)(7) for an offering of pooled investment fund interests.

Is OrbiMed Private Investments X, LP legit?

AltStreet does not rate legitimacy; it reports the public record. OrbiMed Private Investments X, LP filed a Form D with the SEC on October 16, 2026 claiming Rule 506(b), Section 3(c), Section 3(c)(7). A Form D is a notice of an exempt offering, not a review or approval of it. The newest notice reports $1,921,099,472 sold to 131 investors. AltStreet's enforcement record (SEC, FINRA and state actions) shows no action naming the issuer as of today. Before investing, confirm the filing on EDGAR, check the seller's registration on FINRA BrokerCheck, and read the offering documents, which a Form D does not include.

Is OrbiMed Private Investments X, LP registered with or approved by the SEC?

No. A Form D is a notice that an issuer is selling securities under an exemption from registration, and the SEC does not review, approve, or pass on the merits of the offering. The filing shows that OrbiMed Private Investments X, LP claimed Rule 506(b), Section 3(c), Section 3(c)(7) and disclosed the items the form requires, such as the amount sold, the minimum investment, related persons, and anyone paid to sell the securities. It does not verify the issuer's claims or its business.

How much has OrbiMed Private Investments X, LP raised?

OrbiMed Private Investments X, LP reported $1,921,099,472 sold from 131 investors of a $1,921,099,472 total offering as of the Form D filed October 16, 2026. The filing states that the figure is combined across related vehicles, so it is not this entity's figure alone.

Who can invest in OrbiMed Private Investments X, LP?

The offering relies on Rule 506(b), which permits sales to accredited investors and to no more than 35 non-accredited investors who meet a sophistication standard, and prohibits general solicitation. Because the fund also relies on Section 3(c)(7), each investor must be a qualified purchaser, generally an individual with at least $5 million in investments. The filing reports no non-accredited investors. The filing lists the minimum investment as $0, meaning no minimum was stated.

What is the minimum investment in OrbiMed Private Investments X, LP?

The Form D lists the minimum investment as $0, which means the issuer did not state a minimum on the form. The offering documents, not the Form D, set the actual subscription terms.

Who is selling OrbiMed Private Investments X, LP and how are they paid?

The Form D names UBS Switzerland AG, associated with None; MERRILL LYNCH, PIERCE, FENNER & SMITH INCORPORATED (CRD 7691), associated with None as recipients of sales compensation. Sales commissions are reported as $0 and finders' fees as $0. Form D allows these to be estimates.

Who is behind OrbiMed Private Investments X, LP?

The Form D lists 11 related persons: OrbiMed Capital GP X, LP, executive officer (General Partner of the Issuer (the "GPLP")); OrbiMed Capital GP X LLC, executive officer (General Partner of the GPLP (the "GPLLC")); OrbiMed Advisors LLC, executive officer (Managing Member of the GPLLC ("OrbiMed Advisors")); Mona Ashiya, executive officer (Member of OrbiMed Advisors); David P. Bonita, executive officer (Member of OrbiMed Advisors); Carl L. Gordon, executive officer (Member of OrbiMed Advisors); Geoffrey C. Hsu, executive officer (Member of OrbiMed Advisors); W. Carter Neild, executive officer (Member of OrbiMed Advisors), and 3 more. Form D Item 3 requires executive officers, directors, and promoters of the issuer to be listed.

Where is OrbiMed Private Investments X, LP located?

The issuer's address on its SEC filings is 601 Lexington Avenue, 54th Floor, New York, NY 10022. Its phone number of record is 212-739-6400. It is organized under the laws of Delaware.

How long is the OrbiMed Private Investments X, LP offering open?

The issuer indicated that the offering is not intended to last more than one year. An issuer must amend its Form D annually while a continuing offering stays open; 2 amendments are on record for this CIK.

How large is OrbiMed Private Investments X, LP?

The Form D reports a revenue range of Not Applicable.

AltStreet Verified Issuer badge

Is this your company or fund?

Free claim: add your contact details, website, team and a description to this page. The filed facts stay as filed.

Verified Issuer, $480 a year: AltStreet checks the identity of your company and the authority of the person claiming it against your filings, confirms your contact details on a stated date and again at each renewal, and marks the page so people researching you find a current, attributed profile beside the public filing record. It is not a review of any offering.

Data Methodology

Capital raise figures, investor counts, and filing dates are sourced directly from SEC EDGAR Form D primary documents via the SEC EDGAR submissions API and full-text search index. EDGAR entity profiles and deal-level data are reviewed by AltStreet analysts with backgrounds in corporate finance and securities law — cross-referenced against offering circulars, audited financial statements, and primary regulatory filings before publication. Platform-provided information, where present, is clearly labeled and does not affect EDGAR data or AltStreet editorial coverage. Platforms may request factual corrections for demonstrable inaccuracies by contacting [email protected]. This page does not constitute investment advice.